2-chloro-3-methoxy-6-methylquinoxaline | 888480-66-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-chloro-3-methoxy-6-methylquinoxaline
• 英文别名: 2-Chloro-3-methoxy-6-methylquinoxaline
• CAS: 888480-66-8
• 化学式: C₁₀H₉ClN₂O
• 分子量: 208.647
• InChiKey: YDJIIWCPTSFRHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-3-methoxy-6-methylquinoxaline 、 2,4-二甲氧基苯甲胺 以 二甲基亚砜 为溶剂， 反应 45.0h， 以90%的产率得到2-(2,4-dimethoxybenzylamino)-3-methoxy-6-methylquinoxaline
  参考文献：
  名称：

  WO2006/54830

  摘要：

  公开号：

文献信息

• 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives
  申请人：Gong Young-Dae

  公开号：US20080318963A1

  公开（公告）日：2008-12-25

  The present invention relates to novel quinoxaline-piperazine compounds, 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives and their pharmaceutically acceptable salts, a process for their preparation thereof, and compositions containing such compounds. Therapeutic methods for the treatment of hyperproliferative disorders, including cancers, by administering quinoxalin-piperazine compounds are also included.

  本发明涉及新型喹啉-哌嗪化合物，1-[(6,7-取代烷氧基喹啉基)氨基甲酰基]-4-(杂)芳基哌嗪衍生物及其药学上可接受的盐，以及制备这些化合物的方法和含有这些化合物的组合物。本发明还包括通过给予喹啉-哌嗪化合物治疗增殖性疾病，包括癌症的治疗方法。
• 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives
  申请人：Rexahn Pharmaceuticals, Inc.

  公开号：US08314100B2

  公开（公告）日：2012-11-20

  The present invention related to a novel urea derivative for formula (I): which is useful as an anti-cancer agent, its pharmaceutically acceptable acid addition salt or stereoisomer, and to a process for preparing the urea derivative and an anti-cancer composition comprising the same as an active ingredient.

  本发明涉及一种新的尿素衍生物，化学式为(I)，其可用作抗癌剂，其药学上可接受的酸盐或立体异构体，以及制备该尿素衍生物的方法和包含其作为活性成分的抗癌组合物。
• 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES
  申请人：Korea Research Institute of Chemical Technology

  公开号：US20130053390A1

  公开（公告）日：2013-02-28

  The present invention relates to novel quinoxaline-piperazine compounds, 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives and their pharmaceutically acceptable salts, a process for their preparation thereof, and compositions containing such compounds. Therapeutic methods for the treatment of hyperproliferative disorders, including cancers, by administering quinoxaline-piperazine compounds are also included.

  本发明涉及新型喹喔啉-哌嗪化合物，1-[(6,7-取代烷氧基喹喔啉基)氨基甲酰基]-4-(杂)芳基哌嗪衍生物及其药学上可接受的盐，以及其制备方法和含有这样的化合物的组合物。本发明还包括通过给予喹喔啉-哌嗪化合物治疗增殖性疾病，包括癌症的治疗方法。
• 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors
  申请人：Korea Research Institute of Chemical Technology

  公开号：US08598173B2

  公开（公告）日：2013-12-03

  The present invention relates to novel quioxaline-piperazine compounds, 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives of formula (1): and their pharmaceutically acceptable salts, a process for their preparation thereof, and compositions containing such compounds. Therapeutic methods for the treatment of hyperproliferative disorders, including cancers, by administering quioxalin-piperazine compounds are also included.

  本发明涉及新型喹喔啉-哌嗪化合物，式（1）的1-[(6,7-取代烷氧基喹喔啉基)氨基甲酰基]-4-(杂)芳基哌嗪衍生物及其药学上可接受的盐，其制备方法以及含有这些化合物的组合物。本发明还包括通过给予喹喔啉-哌嗪化合物治疗增殖过度性疾病，包括癌症的治疗方法。
• US8314100B2
  申请人：——

  公开号：US8314100B2

  公开（公告）日：2012-11-20